Realm Therapeutics - First Patient Dosed in Phase 2 Study of PR013
Realm Therapeutics Announces First Patient Dosed in Phase 2 Study of PR013 for the Treatment of Allergic Conjunctivitis
The study is a multi-center, double-blind, randomized evaluation of the effectiveness of PR013 topical ophthalmic solution compared to vehicle for the treatment of allergic conjunctivitis using a modified Conjunctival Allergen Challenge Model (Ora-CAC®) in approximately 90 patients. The Ora-CAC® model has been the accepted standard for the successful development of novel treatments for allergic conjunctivitis in the U.S. for the past three decades.
"With the initiation of our second Phase 2 study in as many weeks, we continue to build out our immunomodulatory pipeline and move one step closer to bringing new treatments to patients" said
About Allergic Conjunctivitis
Allergic conjunctivitis is an ophthalmic disease characterized by inflammation of the conjunctiva as a result of contact with airborne allergens. It can be divided into two main categories:
· Seasonal, the most common form which follows a more predictable course that coincides with seasonal increases in allergens (e.g. pollen) and with less dramatic onset (develops over days to weeks); and
· Perennial, a chronic waxing and waning of reaction due to year round allergen exposure (e.g. dust mites, dander, and molds).
Allergic conjunctivitis affects up to 40% of the U.S. population and up to 20% of the population of
About Realm Therapeutics
Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programs, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.
Forward Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
Outside US: +44 (0) 20 3727 1000
US: +1 212 600 1902
+1 212 600 1902
+44 (0) 20 3727 1000
N+1 Singer (Nominated Adviser and Broker)
+44 (0) 20 7496 3000
This information is provided by RNS